Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raise

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and h

Genmab shares gain as petosemtamab cuts head and neck cancer death risk by 50%, backing William Blai

Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jeffe

Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular sess

U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance

Genmab A/S (NASDAQ:GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive topline res

Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab i

TD Cowen analyst Yaron Werber maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price targ

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mut

Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its invest

Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners wit

The Danish biotech said an experimental drug cut the risk of death and disease progression for ovari

Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encour

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 tri

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated follow-up an

Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective

[url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clin

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasda

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del. ; October 24, 2026 Phase 1/2 study will evalua

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key se

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today positive topline res

Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary

Genmab A/S (NASDAQ: GMAB - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report)

Worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) produc

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and rais

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today positive topline results from the Ph

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective res

As of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfo

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price

Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billio

TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price

 Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westl

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and